Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
Previous Symbol
CUSIPN/A
Phone617-945-5576
Debt
Debt-to-Equity RatioN/A
Current Ratio3.39
Quick Ratio3.91
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.36 million
Price / Sales28.91
Cash FlowN/A
Price / CashN/A
Book Value$2.25 per share
Price / Book3.58
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-25,490,000.00
Net Margins-404.34%
Return on Equity-382.71%
Return on Assets-45.00%
Miscellaneous
Employees53
Outstanding Shares29,990,000
Market Cap$241.71 million
OptionableNot Optionable
Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions
What is Unum Therapeutics' stock symbol?
Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."
How were Unum Therapeutics' earnings last quarter?
Unum Therapeutics Inc (NASDAQ:UMRX) announced its quarterly earnings results on Monday, November, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.29 million. Unum Therapeutics had a negative net margin of 404.34% and a negative return on equity of 382.71%. View Unum Therapeutics' Earnings History.
When is Unum Therapeutics' next earnings date?
What price target have analysts set for UMRX?
4 brokers have issued 1 year price objectives for Unum Therapeutics' shares. Their forecasts range from $20.00 to $21.00. On average, they expect Unum Therapeutics' share price to reach $20.6667 in the next twelve months. This suggests a possible upside of 156.4% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.
What is the consensus analysts' recommendation for Unum Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.
Has Unum Therapeutics been receiving favorable news coverage?
Press coverage about UMRX stock has trended neutral on Sunday, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Unum Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Unum Therapeutics' key competitors?
Some companies that are related to Unum Therapeutics include Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Alder Biopharmaceuticals (ALDR), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Kiniksa Pharmaceuticals (KNSA), Akorn (AKRX), Deciphera Pharmaceuticals (DCPH), Y-mAbs Therapeutics (YMAB), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX) and Athenex (ATNX).
Who are Unum Therapeutics' key executives?
Unum Therapeutics' management team includes the folowing people:
- Dr. Charles Wilson, CEO & Director (Age 53)
- Ms. Christiana Stamoulis, Pres & CFO (Age 47)
- Mr. Michael J. Vasconcelles, Chief Medical Officer (Age 54)
- Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
- Mr. Geoffrey Hodge, Chief Technical Officer & Sr. VP of Operations (Age 53)
When did Unum Therapeutics IPO?
(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.
When did the company's lock-up period expire?
Unum Therapeutics' lock-up period expired on Tuesday, September 25th. Unum Therapeutics had issued 5,770,000 shares in its public offering on March 29th. The total size of the offering was $69,240,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.
Who are Unum Therapeutics' major shareholders?
Unum Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FIL Ltd (3.69%), Jennison Associates LLC (2.98%), BlackRock Inc. (1.34%), Platinum Investment Management Ltd. (0.59%), Renaissance Technologies LLC (0.24%) and Citadel Advisors LLC (0.08%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.
Which institutional investors are selling Unum Therapeutics stock?
Which institutional investors are buying Unum Therapeutics stock?
UMRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Citadel Advisors LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Jane Street Group LLC. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.
How do I buy shares of Unum Therapeutics?
Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Unum Therapeutics' stock price today?
One share of UMRX stock can currently be purchased for approximately $8.06.
How big of a company is Unum Therapeutics?
Unum Therapeutics has a market capitalization of $241.71 million and generates $8.36 million in revenue each year. Unum Therapeutics employs 53 workers across the globe.
What is Unum Therapeutics' official website?
How can I contact Unum Therapeutics?
Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]
MarketBeat Community Rating for Unum Therapeutics (NASDAQ UMRX)
MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote "Outperform" if you believe UMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
